Objective

A key aim of the ARUK UCL Drug Discovery Institute is to combine the expertise of collaborating academic researchers in
neurodegenerative disease biology with high quality innovative drug discovery technologies.
Over the course of one year, the UCL ARUK DDI has developed and run 5 novel phenotypic/reporter gene high throughput screens on libraries varying in
size from 376 to 244,405 compounds, generating over one million data points in the process. Successful prosecution of these large screening campaigns
requires the implementation of optimised automation, efficient screening technologies, validated analysis strategies and the development of suitable
follow up counter screens and orthogonal assays. These approaches are a core component of our strategy towards developing new therapies for
dementia and neurodegenerative diseases, examples of which are highlighted below.